TG Therapeutics, Inc. (TGTX) fair value analysis

Nasdaq · Updated 2026-09-07

TG Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes novel treatments for patients with cancer and autoimmune diseases. The company operates in the United States and conducts its business as a publicly traded entity on the Nasdaq stock exchange.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, TGTX is trading at more than a 25% discount to estimated fair value.

TGTX currently ranks #2 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $46.17
Sector: Healthcare
12-month range: $29.18–$53.52

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: D
Margin trend: Contracting
RSI zone: Neutral
50/200-day trend: Mixed
52-week position: The upper-middle quarter of its range

What our data shows for TGTX

Our model validated 7 trailing price-to-earnings windows for TGTX, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $29.18–$53.52.
The 14-day relative strength index sits at a neutral 63.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for TGTX
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent TGTX news

TickrTrends' derived news-sentiment signal for TGTX is currently leaning positive, computed from recent coverage.

TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade) (NASDAQ:TGTX) (seekingalpha.com, 2026-08-26)
TickrTrends take: TG Therapeutics operates in the Healthcare sector where product lifecycle trajectories significantly influence long-term valuation outcomes. Given TickrTrends' current assessment of undervaluation, an analyst noting that Briumvi's peak sales potential may be distant suggests the market may not be fully pricing in the drug's extended revenue runway. Valuation-focused investors should monitor whether Briumvi adoption accelerates over coming quarters, as this would provide fundamental support for a sustained recovery in the company's valuation metrics.
TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors (NASDAQ:TGTX) (seekingalpha.com, 2026-08-22)
TickrTrends take: TG Therapeutics operates in the Healthcare sector where successful drug commercialization can rapidly expand market opportunity and attract acquisition interest. TickrTrends currently derives an Undervalued verdict for TGTX, suggesting the market may not be fully pricing in the growth potential of Briumvi, particularly if buyout speculation gains momentum. Investors focused on valuation should monitor whether enthusiasm around Briumvi's commercial performance begins to narrow the gap between current market pricing and the company's intrinsic value.
TG Therapeutics: Why I'm Staying Long After The Q2 Selloff (NASDAQ:TGTX) (seekingalpha.com, 2026-08-03)
TickrTrends take: TG Therapeutics operates in the Healthcare sector where valuation metrics can shift significantly following quarterly results and market reactions. Given TickrTrends' current assessment of TGTX as undervalued, investors focused on valuation should monitor whether the Q2 selloff represented a genuine deterioration in fundamentals or created a pricing opportunity relative to the company's actual financial position. The Healthcare sector's sensitivity to clinical developments and earnings surprises means that valuation assessments require ongoing review of both operational performance and market sentiment shifts.

What people are saying

Follow the TGTX conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is TGTX stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), TGTX is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is TGTX's TickrTrends verdict?

TGTX's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does TGTX compare to other Healthcare stocks?

TGTX ranks #2 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is TGTX overbought or oversold?

TGTX's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

TGTX vs ADMA · TGTX vs ALGN · TGTX vs ASTH · TGTX vs AZN · TGTX vs BSX